A phase 3, placebo-controlled, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of K-333 (peretinoin) in patients with complete cure of hepatocellular carcinoma in Asia
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Jan 2018
At a glance
- Drugs Peretinoin (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Kowa
- 09 Jan 2018 Planned End Date changed from 30 Mar 2018 to 31 Jan 2019.
- 31 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2016 New trial record